S Michels

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Promising new treatments for neovascular age-related macular degeneration
    Stephan Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Allgemeines Krankenhaus 8i, 1090 Wien Vienna, Austria
    Expert Opin Investig Drugs 15:779-93. 2006
  2. ncbi request reprint Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone
    Stephan Michels
    Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wien Vienna, Osterreich Austria
    Am J Ophthalmol 141:396-398. 2006
  3. ncbi request reprint Influence of treatment parameters on selectivity of verteporfin therapy
    Stephan Michels
    University Eye Hospital Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 47:371-6. 2006
  4. ncbi request reprint [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]
    S Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Osterreich
    Klin Monbl Augenheilkd 222:480-4. 2005
  5. doi request reprint Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
    G Weigert
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Br J Ophthalmol 92:356-60. 2008
  6. doi request reprint Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study
    S Sacu
    Medical University of Vienna, Department of Ophthalmology, Vienna, Austria
    Br J Ophthalmol 92:1347-51. 2008
  7. doi request reprint Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results
    S Sacu
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Eye (Lond) 23:2223-7. 2009
  8. ncbi request reprint [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]
    R Hahn
    Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Wien, Osterreich
    Ophthalmologe 104:588-93. 2007
  9. doi request reprint Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration
    S Sacu
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Eye (Lond) 23:1404-10. 2009
  10. ncbi request reprint Topographic angiography and optical coherence tomography: a correlation of imaging characteristics
    C Ahlers
    University Eye Hospital Vienna, Vienna, Austria
    Eur J Ophthalmol 15:774-81. 2005

Detail Information

Publications33

  1. ncbi request reprint Promising new treatments for neovascular age-related macular degeneration
    Stephan Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Allgemeines Krankenhaus 8i, 1090 Wien Vienna, Austria
    Expert Opin Investig Drugs 15:779-93. 2006
    ..This review provides an overview on angiogenic mechanisms, potential antiangiogenic treatment strategies and different antiangiogenic drugs with special focus on neovascular AMD...
  2. ncbi request reprint Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone
    Stephan Michels
    Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wien Vienna, Osterreich Austria
    Am J Ophthalmol 141:396-398. 2006
    ..To detect patients with neovascular age-related macular degeneration (AMD) who experience retinal pigment epithelium tears after initial verteporfin therapy combined with intravitreal triamcinolone during early follow-up...
  3. ncbi request reprint Influence of treatment parameters on selectivity of verteporfin therapy
    Stephan Michels
    University Eye Hospital Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 47:371-6. 2006
    ..To improve selectivity of verteporfin therapy (PDT) in neovascular age-related macular degeneration (AMD) using modified treatment parameters...
  4. ncbi request reprint [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]
    S Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Osterreich
    Klin Monbl Augenheilkd 222:480-4. 2005
    ..Anti-VEGF therapy using Ranibizumab is a promising new treatment option for neovascular AMD...
  5. doi request reprint Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
    G Weigert
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Br J Ophthalmol 92:356-60. 2008
    ....
  6. doi request reprint Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study
    S Sacu
    Medical University of Vienna, Department of Ophthalmology, Vienna, Austria
    Br J Ophthalmol 92:1347-51. 2008
    ..To compare early treatment effect of reduced fluence versus standard photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in neovascular age-related macular degeneration...
  7. doi request reprint Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results
    S Sacu
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Eye (Lond) 23:2223-7. 2009
    ..To compare 1-year functional and anatomic outcomes of intravitreal bevacizumab (IVB) and photodynamic therapy plus intravitreal triamcinolone (PDT+IVTA) combination in patients with neovascular age-related macular degeneration (AMD)...
  8. ncbi request reprint [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]
    R Hahn
    Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Wahringer Gurtel 18 20, Wien, Osterreich
    Ophthalmologe 104:588-93. 2007
    ..The aim of this study was to compare intravitreal bevacizumab (IVB) and verteporfin therapy in combination with 4 mg intravitreal triamcinolone (PDT-IVTA) in patients with neovascular age-related macular degeneration (AMD)...
  9. doi request reprint Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration
    S Sacu
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Eye (Lond) 23:1404-10. 2009
    ....
  10. ncbi request reprint Topographic angiography and optical coherence tomography: a correlation of imaging characteristics
    C Ahlers
    University Eye Hospital Vienna, Vienna, Austria
    Eur J Ophthalmol 15:774-81. 2005
    ..OCT and TAG imaging were compared to specify the characteristics of each imaging modality...
  11. doi request reprint Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
    F Prager
    Department of Ophthalmology, Medical University of Vienna, Waehringer Guertel 18 20, 1190 Wien, Austria
    Br J Ophthalmol 93:452-6. 2009
    ....
  12. ncbi request reprint Mechanism of photodynamic occlusion using liposomal Zn(II)-phtalocyanine
    Ursula Schmidt-Erfurth
    Universitaetsklinik für Augenheilkunde und Optometrie, Vienna, Austria
    Curr Eye Res 30:601-12. 2005
    ..To evaluate the potential of liposomal Zinc(II)-phthalocyanine (ZnPc) to selectively target subretinal vasculature...
  13. ncbi request reprint An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Anne E Fung
    Pacific Eye Associates, California Pacific Medical Center, San Francisco, California, USA
    Am J Ophthalmol 143:566-83. 2007
    ..To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD)...
  14. ncbi request reprint Retinal pigment epithelium tears following intravitreal ranibizumab therapy
    Christopher Kiss
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
    Acta Ophthalmol Scand 85:902-3. 2007
    ..RPE tears may occur after intravitreal injection of ranibizumab in patients with neovascular AMD, probably because of the rapid regression of the fibrovascular membrane...
  15. ncbi request reprint Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin)
    Franz Prager
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
    Acta Ophthalmol Scand 85:904-6. 2007
    ..A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin)...
  16. ncbi request reprint Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage
    Eva Stifter
    Department of Ophthalmology, Medical University of Vienna, Austria
    Am J Ophthalmol 144:886-892. 2007
    ..To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages...
  17. ncbi request reprint Sequence of early vascular events after photodynamic therapy
    Stephan Michels
    University Eye Hospital Lübeck, Lubeck, Germany
    Invest Ophthalmol Vis Sci 44:2147-54. 2003
    ..To identify early vascular changes in choroidal neovascularization (CNV) and in adjacent normal choroid, after photodynamic therapy (PDT)...
  18. doi request reprint Changes in retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (avastin) therapy
    Franz Prager
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
    Retina 28:682-8. 2008
    ..To evaluate changes in central retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) therapy...
  19. ncbi request reprint Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results
    Ursula M Schmidt-Erfurth
    University Eye Hospital, Luebeck, Germany
    Ophthalmology 109:2284-94. 2002
    ..To document the anatomic and functional outcome of photodynamic therapy (PDT) in symptomatic choroidal hemangioma..
  20. ncbi request reprint Human macula investigated in vivo with polarization-sensitive optical coherence tomography
    Michael Pircher
    Center for Biomedical Engineering and Physics, Medical University of Vienna, Austria
    Invest Ophthalmol Vis Sci 47:5487-94. 2006
    ..To investigate a depolarizing layer that is visible in polarization-sensitive optical coherence tomography (PS-OCT) images of the retina. To identify this layer and characterize its depolarizing effect quantitatively...
  21. pmc Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
    Matthias Bolz
    Department of Ophthalmology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Br J Ophthalmol 91:785-9. 2007
    ..Study design: Prospective uncontrolled pilot study...
  22. ncbi request reprint Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab
    Christopher Kiss
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
    Retina 26:877-81. 2006
    ..To evaluate the effect of intravitreal bevacizumab on anterior chamber inflammatory activity...
  23. ncbi request reprint Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases
    Ursula Schmidt-Erfurth
    Department of Ophthalmology, General Hospital of Vienna, Medical University of Vienna, Waehringer Strasse 13, A 1090 Vienna, Austria
    Invest Ophthalmol Vis Sci 46:3393-402. 2005
    ..To demonstrate a new generation of three-dimensional (3-D) ultrahigh-resolution optical coherence tomography (UHR OCT) technology for visualization of macular diseases...
  24. ncbi request reprint Verteporfin therapy for choroidal hemangioma: a long-term follow-up
    Stephan Michels
    University Eye Hospital Vienna, Vienna, Austria
    Retina 25:697-703. 2005
    ..To document the long-term follow-up of patients with circumscribed choroidal hemangioma who were treated with verteporfin photodynamic therapy (PDT)...
  25. ncbi request reprint Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration
    Stephan Michels
    Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Vienna, Austria
    Ophthalmology 112:2070-5. 2005
    ..To compare the efficacy and safety of early retreatment with verteporfin therapy with that of approved standard verteporfin therapy in neovascular age-related macular degeneration...
  26. ncbi request reprint Time course and morphology of vascular effects associated with photodynamic therapy
    Ursula Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Ophthalmology 112:2061-9. 2005
    ..To evaluate the time course and morphologic features of verteporfin therapy-induced vascular effects using 3-dimensional topographic angiography (TAG) in patients with choroidal neovascularization (CNV)...
  27. ncbi request reprint Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
    Stephan Michels
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 112:1035-47. 2005
    ..South San Francisco, CA) and its effects on visual acuity (VA) and subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD)...
  28. ncbi request reprint Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor
    Ursula Schmidt-Erfurth
    University Eye Hospital Lübeck, Lubeck, Germany
    Invest Ophthalmol Vis Sci 44:4473-80. 2003
    ..To evaluate the impact of photodynamic therapy (PDT) on expression and distribution of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-3, and pigment epithelium-derived factor (PEDF)...
  29. ncbi request reprint Perspectives on verteporfin therapy combined with intravitreal corticosteroids
    Ursula Schmidt-Erfurth
    Department of Ophthalmology, University of Vienna, Vienna, Austria
    Arch Ophthalmol 124:561-3. 2006
  30. ncbi request reprint Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin
    Ursula M Schmidt-Erfurth
    University Eye Hospital, Medical School Luebeck, Ratzeburger Allee 160, D 13538 Luebeck, Germany
    Ophthalmology 110:1306-14. 2003
    ..To evaluate vascular changes documented by confocal indocyanine green angiography (ICGA) through 2 years after photodynamic therapy (PDT) with verteporfin of neovascular age-related macular degeneration (AMD)...
  31. ncbi request reprint Three-dimensional imaging of pigment epithelial detachment in age-related macular degeneration using optical coherence tomography, retinal thickness analysis and topographic angiography
    Christian Ahlers
    Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Graefes Arch Clin Exp Ophthalmol 244:1233-9. 2006
    ..In this study, advantages and disadvantages of the new imaging methods have been evaluated in patients with serous (sPED) and fibrovascular pigment epithelial detachments (fPED) secondary to age-related macular degeneration (AMD)...
  32. ncbi request reprint Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study
    Andrew A Moshfeghi
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Ophthalmology 113:2002.e1-12. 2006
    ..To evaluate the safety, efficacy, and durability of bevacizumab for the treatment of subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD)...
  33. ncbi request reprint Photodynamic effects on choroidal neovascularization and physiological choroid
    Ursula Schmidt-Erfurth
    Eye Hospital, University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Invest Ophthalmol Vis Sci 43:830-41. 2002
    ..To evaluate the effect of photodynamic therapy (PDT) on perfusion and vascular integrity of choroidal neovascularization (CNV) and collateral physiological choroid...